Nearly a decade after becoming the first PCSK9 inhibitor to receive approval from the FDA, alirocumab (Praluent) has now received approval for pediatric patients with HeFH based on data from a phase 3 trial.
Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia TARRYTOWN, N.Y., March 11, 2024 Regeneron Pharmaceuticals, Inc. announced the.
PCSK9 Inhibitor Access Barrier Risks Heart Attacks, Strokes miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Access to Prescribed PCSK9 Inhibitors Remains a Significant Barrier Leaving Patients at Risk for Heart Attacks and Strokes lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.